Search results
Showing 151 to 165 of 261 results for carcinoma
Flexible endoscopic treatment of a pharyngeal pouch (IPG513)
Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.
In development Reference number: GID-TA10745 Expected publication date: 17 July 2024
Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.
View recommendations for IPG187Show all sections
Sections for IPG187
Discontinued Reference number: GID-TA10397
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.
Show all sections
Photodynamic therapy for early-stage oesophageal cancer (IPG200)
Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.
View recommendations for IPG200Show all sections
Sections for IPG200
Evidence-based recommendations on stent placement for vena caval obstruction. This involves using a catheter to position a stent, which may be self-expanding or balloon-dilated, across the area of narrowing to relieve it.
View recommendations for IPG79Show all sections
Sections for IPG79
Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]
Discontinued Reference number: GID-TAG398
Irreversible electroporation for primary liver cancer (IPG664)
Evidence-based recommendations on irreversible electroporation for primary liver cancer in adults. This involves passing short electrical pulses of high-voltage current into the cancer cells.
View recommendations for IPG664Show all sections
Discontinued Reference number: GID-TA10567
Discontinued Reference number: GID-TA11008
Evidence-based recommendations on laparoscopic liver resection. This involves making small incisions (keyhole surgery) to remove the parts of the liver that are benign or cancerous.
View recommendations for IPG135Show all sections
Sections for IPG135
Interstitial photodynamic therapy for malignant parotid tumours (IPG259)
Evidence-based recommendations on interstitial photodynamic therapy for malignant parotid tumours. This involves injecting a photosensitising agent into a vein and using a special light to activate it and destroy the tumour cells.
View recommendations for IPG259Show all sections
Sections for IPG259